Performing Country-led Economic Evaluations to Inform Immunization Policy: ProVac Experiences in Latin America and the Caribbean


Janusz, CB; Jauregui, B; Sinha, A; Clark, AD; Bolaños, BM; Resch, S; Toscano, C; Andrus, JK; (2012) Performing Country-led Economic Evaluations to Inform Immunization Policy: ProVac Experiences in Latin America and the Caribbean. Value in health regional issues, 1 (2). pp. 248-253. ISSN 2212-1099 DOI: 10.1016/j.vhri.2012.10.003

Full text not available from this repository.

Abstract

New vaccines have been demonstrated to be effective in reducing morbidity and mortality, particularly in children, but come at increased costs to societies, governments, and their national immunization programs compared with other traditional childhood vaccines. Rational allocation of available resources requires systematic collection of the evidence base to decide whether to introduce a new vaccine, an important component of which is cost-effectiveness analysis. In this article, we develop in-depth case studies to examine the country experience of conducting cost-effectiveness analysis with the support of Pan American Health Organization ProVac Initiative and the implications of its process for decision making on new vaccine introduction in Latin America and the Caribbean. Key lessons regarding how cost-effectiveness analysis may be effectively used to inform evidence-based immunization policy are highlighted, drawing from the experience of Nicaragua and Paraguay. Based on the lessons identified, the vision going forward will focus on promoting the sustainability of multidisciplinary country teams while continuing to prioritize capacity development as an overarching guiding principle for preparing countries to face future new vaccine policy decisions. © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Item Type: Article
Keywords: Cost-effectiveness analysis, Economic evaluations, Evidence-based policy, National immunization programs, 10 valent pneumococcal conjugate vaccine, 13 valent pneumococcal conjugate vaccine, Pneumococcus vaccine, unclassified drug, article, case study, Central America, cost effectiveness analysis, drug cost, economic evaluation, evidence based practice, health care organization, health care policy, health care quality, human, immunization, medical decision making, Nicaragua, Paraguay, priority journal, South and Central America
Faculty and Department: Faculty of Public Health and Policy > Dept of Health Services Research and Policy
URI: http://researchonline.lshtm.ac.uk/id/eprint/2064793

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
271Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item